Regeneron

YTD

ALL

Trade Regeneron 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About REGN

Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: Dupixent, Evkeeza, Eylea, Inmazeb, and Kevzara.

CEO

Leonard S. Schleifer

CEOLeonard S. Schleifer

Employees

15,410

Employees15,410

Headquarters

Tarrytown, New York

HeadquartersTarrytown, New York

Founded

1988

Founded1988

Employees

15,410

Employees15,410

REGN Key Statistics

Market cap

80.30B

Market cap80.30B

Price-Earnings ratio

18.44

Price-Earnings ratio18.44

Dividend yield

0.47%

Dividend yield0.47%

Average volume

668.11K

Average volume668.11K

High today

$764.30

High today$764.30

Low today

$747.82

Low today$747.82

Open price

$758.90

Open price$758.90

Volume

561.90K

Volume561.90K

52 Week high

$821.11

52 Week high$821.11

52 Week low

$476.49

52 Week low$476.49

Stock Snapshot

With a market cap of 80.3B, Regeneron(REGN) trades at $757.00. The stock has a price-to-earnings ratio of 18.44 and currently yields dividends of 46.8%.

On 2026-03-07, Regeneron(REGN) stock traded between a low of $747.82 and a high of $764.30. Shares are currently priced at $757.00, which is +1.2% above the low and -1.0% below the high.

The Regeneron(REGN)'s current trading volume is 561.9K, compared to an average daily volume of 668.11K.

During the past year, Regeneron(REGN) stock moved between $476.49 at its lowest and $821.11 at its peak.

REGN News

Simply Wall St 11h

Assessing Regeneron Pharmaceuticals Valuation As Shares Trade Below Estimated Fair Value

Advertisement Regeneron Pharmaceuticals overview Regeneron Pharmaceuticals (REGN) has drawn investor attention after its shares closed at US$764.93, with rece...

TipRanks 21h

Regeneron initiated with an Overweight at Barclays

Barclays initiated coverage of Regeneron (REGN) with an Overweight rating and $923 price target The shares are “fundamentally mispricing” the company’s profits...

TipRanks 4d

Sanofi Wins FDA Nod for Dupixent as First Targeted Treatment for Allergic Fungal Rhinosinusitis

Sanofi ( (SNY) ) has shared an update. On February 24, 2026, Sanofi and Regeneron secured U.S. FDA priority-review approval for Dupixent as the first and only...

Analyst ratings

73%

of 30 ratings

Buy

73.3%

Hold

26.7%

Sell

More REGN News

TipRanks 5d

Regeneron price target raised to $765 from $745 at RBC Capital

RBC Capital analyst Brian Abrahams raised the firm’s price target on Regeneron (REGN) to $765 from $745 and keeps a Sector Perform rating on the shares. The fir...

People also own

Based on the portfolios of people who own REGN. This list is generated using Robinhood data, and it’s not a recommendation.

MercadoLibre

Constellation Brands

abrdn Physical Precious M…

ServiceNow

Cipher Mining

Palo Alto Networks

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.